- Home
- CE vs TMDX Comparison
CE vs TMDX Comparison
Compare CE & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CE
- TMDX
- Stock Information
- Founded
- CE 1918
- TMDX 1998
- Country
- CE United States
- TMDX United States
- Employees
- CE N/A
- TMDX N/A
- Industry
- CE Major Chemicals
- TMDX Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- CE Industrials
- TMDX Health Care
- Exchange
- CE Nasdaq
- TMDX Nasdaq
- Market Cap
- CE 4.5B
- TMDX 3.9B
- IPO Year
- CE 2005
- TMDX 2019
- Fundamental
- Price
- CE $38.70
- TMDX $114.30
- Analyst Decision
- CE Buy
- TMDX Buy
- Analyst Count
- CE 18
- TMDX 11
- Target Price
- CE $57.33
- TMDX $130.73
- AVG Volume (30 Days)
- CE 2.4M
- TMDX 1.0M
- Earning Date
- CE 11-06-2025
- TMDX 10-29-2025
- Dividend Yield
- CE 0.31%
- TMDX N/A
- EPS Growth
- CE N/A
- TMDX 170.70
- EPS
- CE N/A
- TMDX 2.54
- Revenue
- CE $9,710,000,000.00
- TMDX $566,354,000.00
- Revenue This Year
- CE N/A
- TMDX $38.84
- Revenue Next Year
- CE $2.21
- TMDX $20.46
- P/E Ratio
- CE N/A
- TMDX $45.35
- Revenue Growth
- CE N/A
- TMDX 41.20
- 52 Week Low
- CE $35.48
- TMDX $55.00
- 52 Week High
- CE $77.43
- TMDX $145.50
- Technical
- Relative Strength Index (RSI)
- CE 44.71
- TMDX 40.85
- Support Level
- CE $35.48
- TMDX $115.21
- Resistance Level
- CE $42.76
- TMDX $125.57
- Average True Range (ATR)
- CE 1.93
- TMDX 7.65
- MACD
- CE 0.20
- TMDX -1.72
- Stochastic Oscillator
- CE 39.34
- TMDX 12.41
About CE Celanese Corporation
Celanese is one of the world's largest producers of acetic acid and its downstream derivative chemicals, which are used in various end markets, including coatings and adhesives. The company is also one of the largest producers of specialty polymers, which are used in the automotive, electronics, medical, building, and consumer end markets. The company also makes cellulose derivatives used in cigarette filters.
About TMDX TransMedics Group Inc.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.